Olaparib receives FDA approval for HRR gene-mutated metastatic castration-resistant prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has approved olaparib (Lynparza) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, who have progressed following prior treatment with enzalutamide or abiraterone.

Lynparza is sponsored by AstraZeneca Pharmaceuticals LP.

FDA has also approved FoundationOne CDx (sponsored by Foundation Medicine Inc.) for selection of patients with mCRPC carrying HRR gene alterations and BRACAnalysis CDx test (sponsored by Myriad Genetic Laboratories Inc.) for selection of patients with mCRPC carrying germline BRCA1/2 alterations as companion diagnostic devices for treatment with olaparib.

Efficacy was investigated in PROfound (NCT02987543), an open-label, multicenter trial randomizing (2:1) 256 patients to olaparib 300 mg twice daily and 131 patients to investigator’s choice of enzalutamide or abiraterone acetate. All patients received a GnRH analog or had prior bilateral orchiectomy.

Patients were divided into two cohorts based on their HRR gene mutation status. Patients with mutations in either BRCA1, BRCA2, or ATM were randomized in Cohort A (N=245); patients with mutations among 12 other genes involved in the HRR pathway were randomized in Cohort B (N=142); those with co-mutations (Cohort A gene and a Cohort B gene) were assigned to Cohort A.

The major efficacy outcome of the trial was radiological progression-free survival (Cohort A). Additional efficacy outcomes included confirmed objective response rate (ORR) (Cohort A) in patients with measurable disease, rPFS (combined Cohorts A+B), and overall survival (Cohort A).

A statistically significant improvement was demonstrated for olaparib compared to investigator’s choice in Cohort A for rPFS with a median of 7.4 months vs 3.6 months (HR 0.34; 95% CI: 0.25, 0.47; p<0.0001), for OS with a median of 19.1 months vs. 14.7 months (HR 0.69; 95% CI: 0.50, 0.97, p=0.0175) and for ORR 33% vs 2% (p<0.0001). A statistically significant improvement for olaparib compared to investigator’s choice was also demonstrated for rPFS in Cohort A+B, with a median of 5.8 months vs. 3.5 months (HR 0.49; 95% CI: 0.38, 0.63; p<0.0001).

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login